id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-278406-n5e3a09i	Macauley, Precious	CORTICOSTEROIDS IN THE TREATMENT OF SEVERE COVID-19 LUNG DISEASE: THE PULMONOLOGY PERSPECTIVE FROM THE FIRST UNITED STATES EPICENTER	2020-08-21		.txt	text/plain	1495	35	15	While caring for scores of severe COVID-19 lung disease patients and repeatedly witnessing a striking clinicoradiographic response to pulse corticosteroids, we were disheartened by the initial negativity towards corticosteroids expressed by, among others, our infectious disease colleagues (Massachusetts General Hospital, 2020; the use of corticosteroids in pulmonary medicine, including at pulse dose, for certain diffuse lung diseases, a practice that is readily applied even to novel entities such as e-cigarette or vaping product-use associated lung injury (EVALI) that lack any evidence base (Layden et al, 2020) . It is worth considering that corticosteroids were administered based on clinicians' discretion a median of three days into ICU stay at a median dose in methylprednisolone equivalents of 60mg, very different from the one gram of methylprednisolone starting on the day of ICU arrival and continued for three days that has been our practice with severe COVID-19 lung disease.	cache/cord-278406-n5e3a09i.txt	txt/cord-278406-n5e3a09i.txt
